Completed PHASE3 INTERVENTIONAL 2-arm NCT00309491

Randomized Study Comparing Tamoxifen vs. Tamoxifen + Aminoglutethimide in Postmenopausal Receptor-positive Patients

A Randomized Phase III Study Comparing Tamoxifen vs. Tamoxifen + Aminoglutethimide in Postmenopausal, Hormone Receptor-positive Patients

Sponsor: AstraZeneca

Conditions Early-stage Breast Cancer

Interventions Tamoxifen + Aminoglutethimide Tamoxifen alone

Updated 6 times since 2017 Last updated: Oct 13, 2020 Started: Dec 31, 1990 Primary completion: Jan 31, 1996 Completion: Mar 31, 2000

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00309491, this PHASE3 trial focuses on Early-stage Breast Cancer and remains completed. Sponsored by AstraZeneca, it has been updated 6 times since 1990, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Nov 2020 — Jan 2021 [monthly]

Completed PHASE3
Jun 2018 — Nov 2020 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Dec 1990

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca
Austrian Breast & Colorectal Cancer Study Group

Data source: Austrian Breast & Colorectal Cancer Study Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.